- Home
- MCVT vs RDHL Comparison
MCVT vs RDHL Comparison
Compare MCVT & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCVT
- RDHL
- Stock Information
- Founded
- MCVT 2007
- RDHL 2009
- Country
- MCVT United States
- RDHL Israel
- Employees
- MCVT N/A
- RDHL N/A
- Industry
- MCVT Finance Companies
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- MCVT Finance
- RDHL Health Care
- Exchange
- MCVT Nasdaq
- RDHL Nasdaq
- Market Cap
- MCVT 14.7M
- RDHL 13.1M
- IPO Year
- MCVT N/A
- RDHL N/A
- Fundamental
- Price
- MCVT $2.13
- RDHL $8.16
- Analyst Decision
- MCVT
- RDHL
- Analyst Count
- MCVT 0
- RDHL 0
- Target Price
- MCVT N/A
- RDHL N/A
- AVG Volume (30 Days)
- MCVT 133.2K
- RDHL 37.3K
- Earning Date
- MCVT 11-15-2024
- RDHL 10-15-2024
- Dividend Yield
- MCVT N/A
- RDHL N/A
- EPS Growth
- MCVT N/A
- RDHL N/A
- EPS
- MCVT 0.04
- RDHL N/A
- Revenue
- MCVT $3,248,401.00
- RDHL $3,707,000.00
- Revenue This Year
- MCVT N/A
- RDHL $224.90
- Revenue Next Year
- MCVT N/A
- RDHL $82.69
- P/E Ratio
- MCVT $58.52
- RDHL N/A
- Revenue Growth
- MCVT N/A
- RDHL N/A
- 52 Week Low
- MCVT $2.10
- RDHL $6.43
- 52 Week High
- MCVT $3.88
- RDHL $82.00
- Technical
- Relative Strength Index (RSI)
- MCVT 36.04
- RDHL 40.13
- Support Level
- MCVT $2.23
- RDHL $7.95
- Resistance Level
- MCVT $2.47
- RDHL $9.05
- Average True Range (ATR)
- MCVT 0.30
- RDHL 0.61
- MACD
- MCVT -0.08
- RDHL -0.20
- Stochastic Oscillator
- MCVT 0.00
- RDHL 6.73
About MCVT Mill City Ventures III Ltd.
Mill City Ventures III Ltd is a non-bank lender and specialty finance company. The company is engaged in the business of providing short-term specialty finance solutions primarily to private businesses, micro-and small-cap public companies, and high-net-worth individuals. The principal specialty finance solutions that they provide are high-interest short-term lending arrangements. Typically, these lending arrangements involve obtaining collateral as security for the borrower's repayment of funds, or personal guarantees from the principals or affiliates of the borrower.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.